Minimal Important Difference (MID) of Response to the Hepatitis-C Virus Patient Reported Outcomes (HCV-PRO) Instrument in a Trial of Pegylated Interferon/Ribavirin (pegIFN/RBV) and Direct-Acting-Antivirals (DAA)
Abstract
Authors
R.W. Baran R.T. Anderson B. Dietz K. Gooch